Biotech Values

[DewDiligence]

NVS receives FDA approval for Exforge (Diovan+Norvasc). However, NVS has previously stated that it will wait until September (when PFE’s pediatric exclusivity runs out on Norvasc) before launching and today’s PR says nothing to contradict that.

http://biz.yahoo.com/prnews/070621/nyth035.html?.v=98

Given that Teva has launched a generic Lotrel (Lotensin+Norvasc), which has been one of NVS’ biggest-selling branded drugs, I figured NVS might get more aggressive on launching Exforge to offset the Lotrel losses. But evidently they won’t.